FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm

PRESS RELEASE
Published August 22, 2023

LOS ANGELES, CA / ACCESSWIRE / August 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Schall Law Firm, Tuesday, August 22, 2023, Press release picture

Investors who purchased the Company's securities between May 23, 2022 and May 10, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before August 29, 2023.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Immunity Bio failed to conduct appropriate due diligence necessary to discover deficiencies in Good Manufacturing Practice ("GMP") activities at its contract manufacturing organizations ("CMOs") for Anktiva. The Company's CMOs did in fact suffer from GMP problems. These GMP issues were likely to cause the FDA to reject the Company's Biologics License Application ("BLA") for Anktiva. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ImmunityBio, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/775886/FINAL-DEADLINE-ALERT-The-Schall-Law-Firm-Encourages-Investors-in-ImmunityBio-Inc-with-Losses-of-100000-to-Contact-the-Firm

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.